When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?

Long-acting β(2)-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom L...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Hong-Joon, Kim, Yu-Il, Kim, Youlim, Lee, Chang Youl, Ra, Seung Won, Moon, Ji-Yong, Jung, Ki-Suck, Yoo, Kwang Ha, Shin, Kyeong-Cheol, Lim, Sung-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chonnam National University Medical School 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570857/
https://www.ncbi.nlm.nih.gov/pubmed/37840676
http://dx.doi.org/10.4068/cmj.2023.59.3.180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570857/
https://www.ncbi.nlm.nih.gov/pubmed/37840676
http://dx.doi.org/10.4068/cmj.2023.59.3.180

Ejemplares similares